HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Post-Pandemic Stocks

976.811

+21.9542.30%

Number of Gainers:17

Number of Losers:1

Number of Flat:- -

PE:- -

High:984.418

Open:954.770

Low:954.770

Close:954.857

Loading ...

BRIEF-Sino Biopharmaceutical Signs Exclusive Strategic Cooperation Agreement With Sciwind Biosciences

Sino Biopharmaceutical - Signing of an Exclusive Strategic Cooperation Agreement With Sciwind Biosciences

THOMSON REUTERS

Sino Biopharmaceutical - Co, Sciwind Biosciences Established Exclusivity on Licensing and Cooperation in 19 Countries for Human Interleukin-29 Project

THOMSON REUTERS

Fosun Pharmaceutical Gets Marketing Authorization for Chronic Kidney Disease Drug

MT Newswires Live

Fosun Pharmaceutical Unit Gets Chinese Regulator's Nod for Chronic Kidney Disease Tablets

MT Newswires Live

Fosun Pharmaceutical Unit Gets China Nod for Lung Diseases Drug

MT Newswires Live

Fosun Pharmaceutical Unit Gets China Nod for Colon Cleansing Granules

MT Newswires Live

BRIEF-Shanghai Fosun Pharma's Unit Received Marketing Registration Approval From NMPA China For Compound Sodium Picosulfate Granules

CSPC Pharmaceutical's 2024 Profit to Fall 26%; Shares Slide 4%

MT Newswires Live

Calculating The Fair Value Of JD Health International Inc. (HKG:6618)

Simply Wall St.

BRIEF-CSPC Pharmaceutical Expects Decrease In Profit Attributable For Year Of 26%

CSPC Pharmaceutical Sees Decrease in Profit Attributable for Year of 26%

THOMSON REUTERS

CSPC Pharmaceutical - Expected Result Due to Decrease in Revenue of Finished Drugs Business for Year

THOMSON REUTERS

CanSino Biologics Gets Clinical Trial Appproval from NMPA for Influenzae Type B Vaccine

MT Newswires Live

BRIEF-CanSino Biologics Says DTcP-Hib-MCV4 Combined Vaccine Obtains Clinical Trial Approval By NMPA China

BRIEF-Anhui Sunhere Says Shareholder Shanghai Fosun Pharma To Unload Up To 3% Stake

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1515/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":976.81055,"timestamp":1741248510324,"preClose":954.8568,"halted":0,"volume":575283040,"delay":0,"changeRate":0.022992,"change":21.953735,"pbRate":1.681623,"amount":5623531621,"amplitude":0.03105,"prevYearClose":787.97723,"fiveDayClose":966.408,"twentyDayClose":851.934,"turnoverRate":0.007641,"marketCap":671721238880,"floatMarketCap":554131605088,"peRate":21.189191},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":984.418,"amplitude":0.03105,"preClose":954.8568,"low":954.7698,"pbRate":"1.681623","latestPrice":976.81055,"volume":575283040,"delay":0,"open":954.7698,"prevYearClose":787.97723,"prevWeekClose":904.791,"prevMonthClose":904.791,"prevQuarterClose":787.977,"fiveDayClose":966.408,"twentyDayClose":851.934,"sixtyDayClose":807.806,"secType":"PLATE","market":"HK","turnoverRate":0.007641,"peRate":21.189191,"marketCap":671721238880,"floatMarketCap":554131605088,"timestamp":1741248510324,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":17,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514876417","title":"BRIEF-Sino Biopharmaceutical Signs Exclusive Strategic Cooperation Agreement With Sciwind Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2514876417","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514876417?lang=en_us&edition=fundamental","pubTime":"2025-02-27 17:52","pubTimestamp":1740649979,"startTime":"0","endTime":"0","summary":"BRIEF-Sino Biopharmaceutical Signs Exclusive Strategic Cooperation Agreement With Sciwind BiosciencesFeb 27  - Sino Biopharmaceutical Ltd 1177.HK:SIGNING OF AN EXCLUSIVE STRATEGIC COOPERATION AGREEMENT WITH SCIWIND BIOSCIENCES REGARDING PROJECT IL-29SIGNING OF AN EXCLUSIVE STRATEGIC COOPERATION AGREEMENT WITH SCIWIND BIOSCIENCESCO, SCIWIND BIOSCIENCES ESTABLISHED EXCLUSIVITY ON LICENSING AND COOPERATION IN 19 COUNTRIES FOR HUMAN INTERLEUKIN-29 PROJECTFurther company coverage: 1177.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI0KV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","BK1589","BK1515","BK1191","BK1521"],"gpt_icon":0},{"id":"2514822477","title":"Sino Biopharmaceutical - Signing of an Exclusive Strategic Cooperation Agreement With Sciwind Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2514822477","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514822477?lang=en_us&edition=fundamental","pubTime":"2025-02-27 16:40","pubTimestamp":1740645657,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI0KV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1589","01177","BK1515","BK1191","BK1521"],"gpt_icon":0},{"id":"2514230822","title":"Sino Biopharmaceutical - Co, Sciwind Biosciences Established Exclusivity on Licensing and Cooperation in 19 Countries for Human Interleukin-29 Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2514230822","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514230822?lang=en_us&edition=fundamental","pubTime":"2025-02-27 16:40","pubTimestamp":1740645657,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI0KV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1589","BK1515","01177","BK1521","BK1191"],"gpt_icon":0},{"id":"2514434848","title":"Fosun Pharmaceutical Gets Marketing Authorization for Chronic Kidney Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2514434848","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514434848?lang=en_us&edition=fundamental","pubTime":"2025-02-27 11:58","pubTimestamp":1740628689,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  obtained marketing authorization for tenapanol hydrochloride tablets from China's food and drug administrator.The drug is used to control serum phosphorus levels in adult dialysis patients with chronic kidney disease who have inadequate response or intolerance to phosphate binders, according to a Thursday filing with the Shanghai bourse.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0239","BK0187","00656","BK0096","BK1191","BK0028","BK1593","BK0175","02196","BK0060","BK1515","BK0183","BK0012","BK0188","600196"],"gpt_icon":0},{"id":"2514319348","title":"Fosun Pharmaceutical Unit Gets Chinese Regulator's Nod for Chronic Kidney Disease Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2514319348","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514319348?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:21","pubTimestamp":1740572493,"startTime":"0","endTime":"0","summary":"China approved Shanghai Fosun Pharmaceutical  subsidiary Shanghai Fosun Pharmaceutical Industrial Development's tenapanor hydrochloride tablets for an indication of chronic kidney disease, according to a Wednesday filing with the Hong Kong Exchange.The tablets help control serum phosphorus levels in dialysis patients with chronic kidney disease who do not have an adequate response to phosphorus binders, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0239","BK0188","BK0012","BK1191","BK0175","BK0060","BK1515","02196","BK0183","BK0096","BK1593","BK0028","00656","BK0187","600196"],"gpt_icon":0},{"id":"2514675831","title":"Fosun Pharmaceutical Unit Gets China Nod for Lung Diseases Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2514675831","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514675831?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:18","pubTimestamp":1740572317,"startTime":"0","endTime":"0","summary":"China accepted Shanghai Fosun Pharmaceutical  subsidiary Yaopharma's drug registration application for its bromhexine hydrochloride injection, according to a Wednesday filing with the Hong Kong Exchange.The drug is an expectorant indicated for lung ailments such as pulmonary tuberculosis, pneumoconiosis, or postoperative sputum retention, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","600196","BK1515","BK0239","BK0096","BK0060","02196","BK0028","BK0196","BK0012","BK0187","BK1593","00656","BK0188","BK1191","BK0183"],"gpt_icon":0},{"id":"2514315528","title":"Fosun Pharmaceutical Unit Gets China Nod for Colon Cleansing Granules","url":"https://stock-news.laohu8.com/highlight/detail?id=2514315528","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514315528?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:17","pubTimestamp":1740572245,"startTime":"0","endTime":"0","summary":"China granted Shanghai Fosun Pharmaceutical  subsidiary Suzhou Erye Pharmaceutical marketing approval for its compound sodium picosulfate granules for colon cleansing.The drug contains sodium picosulfate, magnesium oxide, and anhydrous citric acid, and is used to clean the colon for colonoscopy or X-rays, and for preparation for colon surgery, according to a Wednesday filing with the Hong Kong Exchange.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0096","BK0196","600196","BK0060","02196","BK0175","BK0183","BK1593","BK0012","BK0028","BK0187","BK0188","BK1191","BK0239","00656","BK1515"],"gpt_icon":0},{"id":"2514898880","title":"BRIEF-Shanghai Fosun Pharma's Unit Received Marketing Registration Approval From NMPA China For Compound Sodium Picosulfate Granules","url":"https://stock-news.laohu8.com/highlight/detail?id=2514898880","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514898880?lang=en_us&edition=fundamental","pubTime":"2025-02-26 18:31","pubTimestamp":1740565889,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma's Unit Received Marketing Registration Approval From NMPA China For Compound Sodium Picosulfate GranulesFeb 26  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:UNIT RECEIVED MARKETING REGISTRATION APPROVAL FROM NMPA CHINA FOR COMPOUND SODIUM PICOSULFATE GRANULESFurther company coverage: 600196.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH0XP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0188","BK1191","BK1515","BK0183","BK0012","02196","BK0187","BK0196","600196","BK0096","BK0028","BK0060","BK0175","BK1593"],"gpt_icon":0},{"id":"2514003247","title":"CSPC Pharmaceutical's 2024 Profit to Fall 26%; Shares Slide 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514003247","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514003247?lang=en_us&edition=fundamental","pubTime":"2025-02-26 14:25","pubTimestamp":1740551131,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group  expects a 26% year-over-year decline in attributable profit for the year 2024 from around 5.87 billion yuan a year prior, a Tuesday filing with the Hong Kong bourse said.The pharmaceutical firm attributed the lower anticipated profit mainly to a decrease in revenue of the finished drugs business.Shares of the company were down nearly 4% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1226287792.SGD","IE0008368742.USD","BK1521","IE00BZ08YR35.GBP","LU1152091754.HKD","IE00B031HY20.USD","LU1226288170.HKD","IE0008369823.USD","LU1152091168.USD","IE00BZ08YS42.EUR","LU1226287529.USD","01093","LU1008478684.HKD","LU1960683339.HKD","LU0326950275.SGD","LU1807302812.USD","IE00B543WZ88.USD","IE00BZ08YT58.USD","BK1191","BK1515","LU0072913022.USD","LU1226288253.USD","SG9999004220.SGD","IE00B5MMRT66.SGD","LU1226287875.USD","LU0067412154.USD","LU0501845795.SGD","LU1951186391.HKD","LU1993786604.SGD","LU0140636845.USD","LU0880133367.SGD"],"gpt_icon":0},{"id":"2514388147","title":"Calculating The Fair Value Of JD Health International Inc. (HKG:6618)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514388147","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514388147?lang=en_us&edition=fundamental","pubTime":"2025-02-26 11:48","pubTimestamp":1740541696,"startTime":"0","endTime":"0","summary":"Key Insights Using the 2 Stage Free Cash Flow to Equity, JD Health International fair value estimate is HK$42.50...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/calculating-the-fair-value-of-jd-health-international-inc-hk-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4505","BK4531","LU0244354667.USD","LU0588546209.SGD","BK4579","BK4524","LU0326950275.SGD","FCF","BK1247","LU1688375341.USD","BK4558","LU1880383366.USD","BK4504","DCF","IE00BGV7N243.SGD","06618","IE0008368742.USD","BK1571","86618","LU0463099449.HKD","SG9999002463.SGD","BK4211","LU0456827905.SGD","BK1589","BK4503","LU1188198961.HKD","BK4526","LU0051755006.USD","BK4509","BK4122","BK1583","BK1515","BK4100","BK4551","BK4585","LU0307460666.USD","BK1591","LU0106959298.USD","BK1142","BK4588","BK4220","TV"],"gpt_icon":1},{"id":"2514060037","title":"BRIEF-CSPC Pharmaceutical Expects Decrease In Profit Attributable For Year Of 26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514060037","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514060037?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:52","pubTimestamp":1740484340,"startTime":"0","endTime":"0","summary":"BRIEF-CSPC Pharmaceutical Expects Decrease In Profit Attributable For Year Of 26%Feb 25  - CSPC Pharmaceutical Group Ltd 1093.HK:SEES DECREASE IN PROFIT ATTRIBUTABLE FOR YEAR OF 26%EXPECTED RESULT DUE TO DECREASE IN REVENUE OF FINISHED DRUGS BUSINESS FOR YEARFurther company coverage: 1093.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0HQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IE0008368742.USD","IE00B543WZ88.USD","IE00B031HY20.USD","LU1152091754.HKD","LU0880133367.SGD","LU1226287792.SGD","LU1993786604.SGD","LU1951186391.HKD","LU0072913022.USD","SG9999004220.SGD","BK1515","LU0501845795.SGD","LU1226288170.HKD","IE00BZ08YR35.GBP","LU0326950275.SGD","LU1960683339.HKD","BK1521","LU1226287529.USD","LU0140636845.USD","IE00B5MMRT66.SGD","LU1226288253.USD","01093","LU0067412154.USD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","LU1152091168.USD","IE0008369823.USD","LU1008478684.HKD","LU1807302812.USD","LU1226287875.USD"],"gpt_icon":0},{"id":"2514959060","title":"CSPC Pharmaceutical Sees Decrease in Profit Attributable for Year of 26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514959060","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514959060?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:46","pubTimestamp":1740484007,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0HQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0880133367.SGD","IE0008368742.USD","LU1008478684.HKD","LU1152091754.HKD","LU0501845795.SGD","LU1960683339.HKD","LU1226288253.USD","LU0067412154.USD","IE00BZ08YR35.GBP","LU1951186391.HKD","LU0326950275.SGD","LU1226287529.USD","LU1993786604.SGD","IE00B543WZ88.USD","IE00BZ08YS42.EUR","LU0072913022.USD","LU1152091168.USD","IE00B5MMRT66.SGD","LU1226288170.HKD","LU1226287875.USD","BK1515","01093","IE0008369823.USD","SG9999004220.SGD","BK1191","BK1521","LU1807302812.USD","IE00B031HY20.USD","LU0140636845.USD","LU1226287792.SGD","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2514609550","title":"CSPC Pharmaceutical - Expected Result Due to Decrease in Revenue of Finished Drugs Business for Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2514609550","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514609550?lang=en_us&edition=fundamental","pubTime":"2025-02-25 19:46","pubTimestamp":1740484007,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0HQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1960683339.HKD","LU1226288170.HKD","LU1807302812.USD","LU0501845795.SGD","LU0326950275.SGD","IE00B543WZ88.USD","LU1951186391.HKD","IE00B031HY20.USD","IE00BZ08YS42.EUR","LU1152091168.USD","IE0008369823.USD","LU1226287529.USD","BK1521","01093","LU0880133367.SGD","IE0008368742.USD","LU1008478684.HKD","BK1515","LU1993786604.SGD","LU0140636845.USD","LU1226287792.SGD","LU1226287875.USD","LU1226288253.USD","LU0072913022.USD","IE00BZ08YR35.GBP","LU1152091754.HKD","IE00B5MMRT66.SGD","BK1191","SG9999004220.SGD","IE00BZ08YT58.USD","LU0067412154.USD"],"gpt_icon":0},{"id":"2513749028","title":"CanSino Biologics Gets Clinical Trial Appproval from NMPA for Influenzae Type B Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2513749028","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513749028?lang=en_us&edition=fundamental","pubTime":"2025-02-24 19:00","pubTimestamp":1740394825,"startTime":"0","endTime":"0","summary":"CanSino Biologics  said it obtained clinical trial approval granted by China's National Medical Products Administration to initiate a clinical trial for the Company's Influenzae Type B, according to a Monday filing with the Hong Kong bourse.The DTcP-Hib-MCV4 Combined Vaccine contains components for diphtheria, tetanus, and acellular pertussis , Haemophilus Influenzae Type b , and Group ACYW135 meningococcal  protection.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK1574","BK0239","688185","BK1191","BK1161","06185"],"gpt_icon":0},{"id":"2513823746","title":"BRIEF-CanSino Biologics Says DTcP-Hib-MCV4 Combined Vaccine Obtains Clinical Trial Approval By NMPA China","url":"https://stock-news.laohu8.com/highlight/detail?id=2513823746","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513823746?lang=en_us&edition=fundamental","pubTime":"2025-02-24 18:20","pubTimestamp":1740392406,"startTime":"0","endTime":"0","summary":"BRIEF-CanSino Biologics Says DTcP-Hib-MCV4 Combined Vaccine Obtains Clinical Trial Approval By NMPA ChinaFeb 24  - CanSino Biologics Inc 688185.SS:DTCP-HIB-MCV4 COMBINED VACCINE OBTAINS CLINICAL TRIAL APPROVAL BY NMPA CHINAFurther company coverage: 688185.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF10W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","BK0239","688185","BK1191","BK1161","06185"],"gpt_icon":0},{"id":"2513730498","title":"BRIEF-Anhui Sunhere Says Shareholder Shanghai Fosun Pharma To Unload Up To 3% Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2513730498","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513730498?lang=en_us&edition=fundamental","pubTime":"2025-02-23 21:31","pubTimestamp":1740317465,"startTime":"0","endTime":"0","summary":"BRIEF-Anhui Sunhere Says Shareholder Shanghai Fosun Pharma To Unload Up To 3% Stake Feb 23  - Anhui Sunhere 300452.SZ:SAYS SHAREHOLDER SHANGHAI FOSUN PHARMACEUTICAL PLANS TO UNLOAD UP TO 3% STAKE IN THREE MONTHSSource textFurther company coverage: 300452.SZ  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250223:nL3N3PE02D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK0177","BK0183","BK0187","BK0196","BK0096","BK1593","BK0060","BK0188","BK1515","600196","BK0175","BK0028","300452","02196","BK0012","BK0239"],"gpt_icon":0}],"pageSize":16,"totalPage":3,"pageCount":2,"totalSize":40}]}}